DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
LFCR logo

Lifecore Biomedical, Inc. Stock Price

NasdaqGS:LFCR Community·US$154.8m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

LFCR Share Price Performance

US$4.09
-3.68 (-47.36%)
​
US$6.67
Fair Value
US$4.09
-3.68 (-47.36%)
38.7% undervalued intrinsic discount
US$6.67
Fair Value
Price US$4.09
AnalystConsensusTarget US$6.67
AnalystLowTarget US$5.00
AnalystHighTarget US$10.00
Thu, 11 Jun 26
Fair ValueUS$6.67
Share Pricen/a

LFCR Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$6.67 38.7% undervalued intrinsic discount

Biopharma Partnerships And Injectable Demand Will Expand Global Reach

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$5 18.2% undervalued intrinsic discount

Injectable Manufacturing Demand And Regionalization Trends Will Support Steady Long Term Earnings Improvement

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$10 59.1% undervalued intrinsic discount

Injectable Manufacturing Shift And Late Stage Pipeline Will Transform This Undervalued CDMO

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
LFCR logo
Lifecore Biomedical
18.2% undervalued intrinsic discount

Injectable Manufacturing Demand And Regionalization Trends Will Support Steady Long Term Earnings Improvement

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 26 Jun
Read Narrative
LFCR logo
Lifecore Biomedical
38.7% undervalued intrinsic discount

Biopharma Partnerships And Injectable Demand Will Expand Global Reach

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 11 Jun
Read Narrative
LFCR logo
Lifecore Biomedical
59.1% undervalued intrinsic discount

Injectable Manufacturing Shift And Late Stage Pipeline Will Transform This Undervalued CDMO

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Published 8 Jan
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
LFCR logo

LFCR: New Pharma Agreements Will Shape A Measured Outlook Ahead

Fair Value: US$5 18.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
LFCR logo

LFCR: CDMO Site Transfers And 2028 Ramps Will Drive Long Term Upside

Fair Value: US$6.67 38.7% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
LFCR logo

Injectable Manufacturing Shift And Late Stage Pipeline Will Transform This Undervalued CDMO

Fair Value: US$10 59.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Good value with mediocre balance sheet.

1 Risk
2 Rewards
View Full Analysis

Lifecore Biomedical, Inc. Key Details

US$129.5m

Revenue

US$88.9m

Cost of Revenue

US$40.6m

Gross Profit

US$75.1m

Other Expenses

-US$34.5m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.91
31.37%
-26.65%
383.3%
View Full Analysis

About LFCR

Founded
1965
Employees
382
CEO
Paul Josephs
WebsiteView website
www.lifecore.com

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Recent LFCR News & Updates

Recent updates

No updates

Lifecore Biomedical, Inc. Competitors

DNA logo

Ginkgo Bioworks Holdings

Symbol: NYSE:DNA
Market cap: US$457.2m
IKT logo

Inhibikase Therapeutics

Symbol: NasdaqCM:IKT
Market cap: US$438.8m
RLMD logo

Relmada Therapeutics

Symbol: NasdaqCM:RLMD
Market cap: US$436.3m
NIKA logo

Nika Pharmaceuticals

Symbol: OTCPK:NIKA
Market cap: US$431.2m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide